Six key growth drivers fueled 26% YoY growth, contributing nearly 70% of Q2 sales. Total revenues rose 10% to $10.1B, with strong performance in rare disease, oncology, and biosimilars. 2026 guidance was raised for both revenue and EPS, reflecting confidence in continued momentum.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.